Brief: FDA Issues Complete Response Letter For Etripamil For PSVT
28/03/2025 11:53
March 28 (Reuters) - Milestone Pharmaceuticals Inc MIST.O: FDA ISSUES COMPLETE RESPONSE LETTER FOR ETRIPAMIL FOR PSVT MILESTONE PHARMACEUTICALS INC - FDA RAISES NO CONCERNS ON ETRIPAMIL CLINICAL SAFETY OR EFFICACY MILESTONE PHARMACEUTICALS INC - CRL FOCUSED ON CMC; NO CLINICAL ISSUES RELATING TO ETRIPAMIL RAISED MILESTONE PHARMACEUTICALS INC - COMPANY TO SUBMIT ADDITIONAL INFO ON NITROSAMINE IMPURITIES MILESTONE PHARMACEUTICALS INC - INSPECTION REQUIRED AT FACILITY PERFORMING ETRIPAMIL RELEASE TESTING Source text: ID:nGNXZV9tl Further company coverage: MIST.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Milestone Pharmaceuticals
See all newsBrief: Milestone Pharmaceuticals Announces First European Study Participant Enrolled In Revera-301 Phase 3 Clinical Trial
Brief: Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co
Milestone Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Canada's Milestone Pharma misses Q2 product revenue expectations
Milestone Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview